Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.245 USD | -7.36% | +14.40% | -26.58% |
May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.58% | 631M | |
+8.67% | 114B | |
+11.13% | 104B | |
-12.94% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.09% | 17.89B | |
+7.87% | 14.28B | |
+35.41% | 12.55B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023